KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Net Margin: 2018-2025

Historic Net Margin for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to 42.95%.

  • Aurinia Pharmaceuticals' Net Margin rose 2183.00% to 42.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.30%, marking a year-over-year increase of 3959.00%. This contributed to the annual value of 2.44% for FY2024, which is 4693.00% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Net Margin of 42.95% as of Q3 2025, which was up 39.75% from 30.73% recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Net Margin's 5-year high stood at 42.95% during Q3 2025, with a 5-year trough of -5,511.93% in Q1 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Net Margin value was 1.19% (recorded in 2024), while the average stood at -6.71%.
  • Data for Aurinia Pharmaceuticals' Net Margin shows a peak YoY increase of 14,493,322bps (in 2021) and a maximum YoY decrease of 12,623bps (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Net Margin stood at -142.38% in 2021, then spiked by 5,078bps to -91.60% in 2022, then skyrocketed by 3,191bps to -59.69% in 2023, then spiked by 6,215bps to 2.46% in 2024, then spiked by 2,183bps to 42.95% in 2025.
  • Its Net Margin was 42.95% in Q3 2025, compared to 30.73% in Q2 2025 and 37.37% in Q1 2025.